Carna Biosciences, Inc. (4572.T)
JPY 282.0
(0.0%)
JPY 282.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.15 Billion JPY | 14.57% |
| 2022 | -1.34 Billion JPY | -152.5% |
| 2021 | -534.47 Million JPY | 51.89% |
| 2020 | -1.11 Billion JPY | -234.14% |
| 2019 | 828.28 Million JPY | 168.42% |
| 2018 | -1.21 Billion JPY | -64.2% |
| 2017 | -737.26 Million JPY | -154.28% |
| 2016 | -289.94 Million JPY | -163.53% |
| 2015 | 456.38 Million JPY | 153.9% |
| 2014 | -846.71 Million JPY | -199.89% |
| 2013 | -282.34 Million JPY | 37.26% |
| 2012 | -449.99 Million JPY | -24.43% |
| 2011 | -361.65 Million JPY | 8.93% |
| 2010 | -397.1 Million JPY | -25.91% |
| 2009 | -315.39 Million JPY | 37.3% |
| 2008 | -503.03 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -695.22 Million JPY | -74.29% |
| 2024 Q1 | -398.89 Million JPY | -615.04% |
| 2023 Q1 | -519.2 Million JPY | 6.33% |
| 2023 Q2 | -366.39 Million JPY | 29.43% |
| 2023 Q4 | 77.44 Million JPY | 122.47% |
| 2023 FY | -1.15 Billion JPY | 14.57% |
| 2023 Q3 | -344.73 Million JPY | 5.91% |
| 2022 Q2 | -344.01 Million JPY | -2177.64% |
| 2022 FY | -1.34 Billion JPY | -152.5% |
| 2022 Q4 | -554.32 Million JPY | -27.11% |
| 2022 Q1 | -15.1 Million JPY | -102.35% |
| 2022 Q3 | -436.09 Million JPY | -26.77% |
| 2021 Q4 | 643.6 Million JPY | 260.26% |
| 2021 FY | -534.47 Million JPY | 51.89% |
| 2021 Q1 | -286.33 Million JPY | 38.01% |
| 2021 Q2 | -490.14 Million JPY | -71.18% |
| 2021 Q3 | -401.6 Million JPY | 18.06% |
| 2020 Q4 | -461.89 Million JPY | -83.57% |
| 2020 Q3 | -251.62 Million JPY | -18.07% |
| 2020 Q2 | -213.11 Million JPY | -15.57% |
| 2020 Q1 | -184.39 Million JPY | 35.24% |
| 2020 FY | -1.11 Billion JPY | -234.14% |
| 2019 FY | 828.28 Million JPY | 168.42% |
| 2019 Q4 | -284.76 Million JPY | -244.06% |
| 2019 Q2 | 1.43 Billion JPY | 704.96% |
| 2019 Q1 | -236.81 Million JPY | 38.91% |
| 2019 Q3 | -82.76 Million JPY | -105.78% |
| 2018 Q2 | -295.2 Million JPY | -51.79% |
| 2018 Q3 | -333.24 Million JPY | -12.89% |
| 2018 Q1 | -194.48 Million JPY | 15.05% |
| 2018 FY | -1.21 Billion JPY | -64.2% |
| 2018 Q4 | -387.64 Million JPY | -16.32% |
| 2017 Q3 | -192.18 Million JPY | 2.69% |
| 2017 Q2 | -197.49 Million JPY | -66.46% |
| 2017 Q1 | -118.64 Million JPY | -6.31% |
| 2017 FY | -737.26 Million JPY | -154.28% |
| 2017 Q4 | -228.94 Million JPY | -19.13% |
| 2016 Q3 | -144.58 Million JPY | -549.31% |
| 2016 Q1 | -11.48 Million JPY | 90.09% |
| 2016 FY | -289.94 Million JPY | -163.53% |
| 2016 Q4 | -111.6 Million JPY | 22.81% |
| 2016 Q2 | -22.26 Million JPY | -93.88% |
| 2015 FY | 456.38 Million JPY | 153.9% |
| 2015 Q3 | -94.04 Million JPY | -116.43% |
| 2015 Q4 | -115.93 Million JPY | -23.27% |
| 2015 Q2 | 572.29 Million JPY | 508.36% |
| 2015 Q1 | 94.07 Million JPY | 120.61% |
| 2014 Q2 | -146.27 Million JPY | -31.14% |
| 2014 FY | -846.71 Million JPY | -199.89% |
| 2014 Q1 | -111.53 Million JPY | -28.63% |
| 2014 Q3 | -132.43 Million JPY | 9.46% |
| 2014 Q4 | -456.47 Million JPY | -244.69% |
| 2013 Q1 | -71.53 Million JPY | 25.09% |
| 2013 Q4 | -86.71 Million JPY | -94.37% |
| 2013 Q3 | -44.61 Million JPY | 43.87% |
| 2013 Q2 | -79.48 Million JPY | -11.12% |
| 2013 FY | -282.34 Million JPY | 37.26% |
| 2012 Q3 | -129.89 Million JPY | -20.68% |
| 2012 Q4 | -95.49 Million JPY | 26.49% |
| 2012 FY | -449.99 Million JPY | -24.43% |
| 2012 Q2 | -107.63 Million JPY | 7.99% |
| 2012 Q1 | -116.97 Million JPY | -122.45% |
| 2011 Q1 | -80.71 Million JPY | 20.09% |
| 2011 Q3 | -103.44 Million JPY | 17.18% |
| 2011 Q4 | -52.58 Million JPY | 49.17% |
| 2011 FY | -361.65 Million JPY | 8.93% |
| 2011 Q2 | -124.9 Million JPY | -54.76% |
| 2010 FY | -397.1 Million JPY | -25.91% |
| 2010 Q1 | -95.58 Million JPY | 24.16% |
| 2010 Q3 | -138.32 Million JPY | -122.44% |
| 2010 Q4 | -101 Million JPY | 26.98% |
| 2010 Q2 | -62.18 Million JPY | 34.94% |
| 2009 FY | -315.39 Million JPY | 37.3% |
| 2009 Q1 | -82.95 Million JPY | 0.0% |
| 2009 Q2 | -79.47 Million JPY | 4.19% |
| 2009 Q3 | -26.92 Million JPY | 66.12% |
| 2009 Q4 | -126.03 Million JPY | -368.06% |
| 2008 FY | -503.03 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 400.233% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | -118.801% |
| GNI Group Ltd. | 8.09 Billion JPY | 114.243% |
| Linical Co., Ltd. | 338.26 Million JPY | 440.825% |
| Trans Genic Inc. | 4.08 Million JPY | 28322.644% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 19.824% |
| Soiken Holdings Inc. | -662.2 Million JPY | -74.1% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 934.494% |
| AnGes, Inc. | -7.43 Billion JPY | 84.499% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 10.499% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 83.972% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 717.532% |
| NanoCarrier Co., Ltd. | -780 Million JPY | -47.807% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 4.641% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | -41.91% |
| RaQualia Pharma Inc. | -323.66 Million JPY | -256.203% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 5.502% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 18.929% |
| PeptiDream Inc. | 3.03 Billion JPY | 137.976% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 40.527% |
| Ribomic Inc. | -1.02 Billion JPY | -12.561% |
| SanBio Company Limited | -2.64 Billion JPY | 56.396% |
| Healios K.K. | -3.82 Billion JPY | 69.843% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 1.3% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 22.604% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 19.344% |
| StemRIM | -2.02 Billion JPY | 42.982% |
| CellSource Co., Ltd. | 923.14 Million JPY | 224.888% |
| FunPep Company Limited | -933.41 Million JPY | -23.514% |
| Kringle Pharma, Inc. | -854.15 Million JPY | -34.976% |
| Stella Pharma Corporation | -763.74 Million JPY | -50.952% |
| TMS Co., Ltd. | -960.04 Million JPY | -20.088% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | -2.025% |
| Cuorips Inc. | -632.18 Million JPY | -82.367% |
| K Pharma,Inc. | 260.33 Million JPY | 542.859% |
| Takara Bio Inc. | 1.48 Billion JPY | 177.898% |
| ReproCELL Incorporated | -31.41 Million JPY | -3569.887% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 4470.669% |
| StemCell Institute Inc. | 310.98 Million JPY | 470.728% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 905.269% |
| CellSeed Inc. | -846.53 Million JPY | -36.19% |